RecruitingNCT07034339

Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution


Sponsor

First Affiliated Hospital of Zhejiang University

Enrollment

1,500 participants

Start Date

May 21, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The intricate interplay between systemic immunity and tumors profoundly influences not only the onset and progression of tumors but also serves as a crucial window into understanding tumor evolution and treatment status. This project aims to establish a large, multi-center pancreatic cancer cohort and a standardized clinical sample repository, capturing multimodal immunity big data on pancreatic cancer occurrence, progression, and treatment response across the spatial dimension of "peripheral versus local" and the temporal dimension of "tumor evolution/pre- and post-treatment." By integrating patient imaging and clinical information, the investigators will develop a technical platform for intelligent extraction and fusion analysis of cross-scale, multimodal data, thereby mapping the immunity landscape of pancreatic cancer evolution, identifying characteristic changes in immunity parameters, and devising an AI model for early pancreatic cancer diagnosis with high accuracy and robust generalization capabilities, while also exploring the model's interpretability. Additionally, the investigators will focus on specific immune cell subsets associated with pancreatic cancer evolution and treatment response, elucidating their roles and mechanisms in the occurrence, development, and drug resistance of pancreatic cancer. This project will establish a high-quality, standardized, and shareable pancreatic cancer immunity sample and data repository, refine the framework for multi-dimensional immunity data fusion and analysis, and create a time-space atlas of local and systemic immunity in pancreatic cancer. This will facilitate a deeper understanding of the dynamics of systemic and local immunity in early-stage pancreatic cancer and at various stages of its evolution, offering novel insights and approaches for the diagnosis and treatment of pancreatic cancer.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study maps the immune environment of pancreatic cancer at different stages of progression — from healthy tissue to benign tumours to cancer — to understand how the immune system responds and potentially identify new treatment targets. **You may be eligible if...** - You are a healthy individual with no known liver, gallbladder, or pancreatic disease, OR - You have been diagnosed with pancreatic cancer (PDAC), a benign pancreatic tumour, or a pre-cancerous condition called IPMN **You may NOT be eligible if...** - You have an autoimmune disease - You have another active cancer (except thyroid or breast cancer cured more than 5 years ago) - You have an acute infection - You have had a blood transfusion or taken drugs affecting blood cell counts in the past 6 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

the First Affliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07034339


Related Trials